ImmuPharma (LON:IMM) Trading Down 3.5% - Time to Sell?

Key Points

• ImmuPharma plc stock fell by 3.5% on Wednesday, trading as low as GBX 10.58 ($0.14) and closing at GBX 11.67 ($0.16).
• The company's market cap is £58.47 million and it has a significant negative price-to-earnings ratio of -1,314.61 with a projected EPS of -339 for the current year.
• ImmuPharma is focused on developing peptide-based therapeutics, with its lead program, P140 (Lupuzor™), aimed at treating autoimmune diseases such as Lupus.

ImmuPharma plc (LON:IMM - Get Free Report) fell 3.5% on Wednesday . The stock traded as low as GBX 10.58 ($0.14) and last traded at GBX 11.67 ($0.16). 8,030,504 shares traded hands during trading, a decline of 6% from the average session volume of 8,560,709 shares. The stock had previously closed at GBX 12.10 ($0.16).

ImmuPharma Stock Performance

The business has a 50-day simple moving average of GBX 4.66 and a 200-day simple moving average of GBX 3.39. The company has a market cap of £58.47 million, a price-to-earnings ratio of -1,314.61 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Research analysts anticipate that ImmuPharma plc will post -339.0000022 EPS for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.